These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 29273632)

  • 1. Oncogenic Ras Isoforms Signaling Specificity at the Membrane.
    Nussinov R; Tsai CJ; Jang H
    Cancer Res; 2018 Feb; 78(3):593-602. PubMed ID: 29273632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is Nanoclustering essential for all oncogenic KRas pathways? Can it explain why wild-type KRas can inhibit its oncogenic variant?
    Nussinov R; Tsai CJ; Jang H
    Semin Cancer Biol; 2019 Feb; 54():114-120. PubMed ID: 29307569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
    Nussinov R; Zhang M; Tsai CJ; Jang H
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas.
    Nussinov R; Muratcioglu S; Tsai CJ; Jang H; Gursoy A; Keskin O
    Mol Cancer Res; 2015 Sep; 13(9):1265-73. PubMed ID: 26085527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrinsic protein disorder in oncogenic KRAS signaling.
    Nussinov R; Jang H; Tsai CJ; Liao TJ; Li S; Fushman D; Zhang J
    Cell Mol Life Sci; 2017 Sep; 74(17):3245-3261. PubMed ID: 28597297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The quaternary assembly of KRas4B with Raf-1 at the membrane.
    Jang H; Zhang M; Nussinov R
    Comput Struct Biotechnol J; 2020; 18():737-748. PubMed ID: 32257057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers.
    Guruvaiah P; Gupta R
    J Transl Med; 2024 Jul; 22(1):642. PubMed ID: 38982514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isoform-specific Ras signaling is growth factor dependent.
    Hood FE; Klinger B; Newlaczyl AU; Sieber A; Dorel M; Oliver SP; Coulson JM; Blüthgen N; Prior IA
    Mol Biol Cell; 2019 Apr; 30(9):1108-1117. PubMed ID: 30785867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ras protein abundance correlates with Ras isoform mutation patterns in cancer.
    Hood FE; Sahraoui YM; Jenkins RE; Prior IA
    Oncogene; 2023 Apr; 42(15):1224-1232. PubMed ID: 36864243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of oncogenic RAS on redox balance and implications for cancer development.
    Lim JKM; Leprivier G
    Cell Death Dis; 2019 Dec; 10(12):955. PubMed ID: 31852884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic KRas mobility in the membrane and signaling response.
    Nussinov R; Tsai CJ; Jang H
    Semin Cancer Biol; 2019 Feb; 54():109-113. PubMed ID: 29499269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection and Quantitation of Endogenous Membrane-Bound RAS Proteins and KRAS Mutants in Cancer Cell Lines Using 1D-SDS-PAGE LC-MS
    Kaczmarczyk JA; Whiteley GR; Blonder J
    Methods Mol Biol; 2024; 2823():269-289. PubMed ID: 39052226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of RAS protein interactions in living cells reveals a mechanism for pan-RAS depletion by membrane-targeted RAS binders.
    Li YC; Lytle NK; Gammon ST; Wang L; Hayes TK; Sutton MN; Bast RC; Der CJ; Piwnica-Worms D; McCormick F; Wahl GM
    Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12121-12130. PubMed ID: 32424096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of wild type RAS isoforms in cancer.
    Zhou B; Der CJ; Cox AD
    Semin Cell Dev Biol; 2016 Oct; 58():60-9. PubMed ID: 27422332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calmodulin and PI3K Signaling in
    Nussinov R; Wang G; Tsai CJ; Jang H; Lu S; Banerjee A; Zhang J; Gaponenko V
    Trends Cancer; 2017 Mar; 3(3):214-224. PubMed ID: 28462395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling.
    Rukhlenko OS; Khorsand F; Krstic A; Rozanc J; Alexopoulos LG; Rauch N; Erickson KE; Hlavacek WS; Posner RG; Gómez-Coca S; Rosta E; Fitzgibbon C; Matallanas D; Rauch J; Kolch W; Kholodenko BN
    Cell Syst; 2018 Aug; 7(2):161-179.e14. PubMed ID: 30007540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the RAS-dependent chemoresistance: The Warburg connection.
    Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
    Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating The Role Of Nitric Oxide Synthase In Oncogenic Ras-Driven Tumorigenesis.
    Counter C
    Redox Biol; 2015 Aug; 5():417. PubMed ID: 28162280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer ETS rearrangements switch a cell migration gene expression program from RAS/ERK to PI3K/AKT regulation.
    Selvaraj N; Budka JA; Ferris MW; Jerde TJ; Hollenhorst PC
    Mol Cancer; 2014 Mar; 13():61. PubMed ID: 24642271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of Isoform- and Mutation-Specific RAS Antibodies.
    Waters AM; Der CJ
    Methods Mol Biol; 2021; 2262():91-103. PubMed ID: 33977472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.